QuidelOrtho Posts Q3 2026 Results, Plans $80M Cost Overhaul
QuidelOrtho reported third-quarter 2026 earnings, citing lab and immunohematology growth outside China and a restructuring program targeting over $80M in annual savings.
QuidelOrtho released its third-quarter 2026 financial results, pointing to growth in its Labs and Immunohematology segments outside of China as evidence of underlying business strength even as the company navigates a broader strategic reset.
The diagnostics company announced a new Cost Transformation and Enterprise Restructuring Program designed to generate more than $80 million in annual savings by 2027. The initiative signals a deliberate push to streamline operations and improve profitability across the organization.
Read more Platinum Equity Buys Warren Valve in Energy Infrastructure Deal →
Management also updated its full-year 2026 financial guidance, narrowing the prior outlook range — a move that typically reflects greater visibility into revenue and expense trends as the fiscal year progresses toward its close.
The results underscore a split picture for QuidelOrtho: momentum in key diagnostic segments in certain international markets contrasts with continued headwinds in China, a geography that has weighed on results for several quarters across the broader medical-device and diagnostics sector.
Analysts and investors are likely to focus on the pace and execution of the restructuring program, as well as whether ex-China growth in Labs and Immunohematology can offset lingering pressure in that market. Continue reading at Earnings.
